Insmed (INSM) – Analyst EPS View
-
Stifel Reiterates Buy Rating and $23 PT on Insmed (INSM) Following Meetings with CEO; 'P3 Powered for Success'
-
US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
-
-
-
-
-
Back to INSM Stock Lookup